BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9849586)

  • 1. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1061-6. PubMed ID: 9849586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1055-60. PubMed ID: 9849585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.
    Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
    Jpn J Cancer Res; 1999 Jun; 90(6):685-90. PubMed ID: 10429662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.
    Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1067-73. PubMed ID: 9849587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of amrubicin with a 5 day administration schedule in a mouse model].
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Gan To Kagaku Ryoho; 1999 Aug; 26(9):1305-12. PubMed ID: 10478184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline].
    Hanada M; Noguchi T; Murayama T
    Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):141-50. PubMed ID: 12890900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
    Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
    Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
    Hanada M; Noguchi T; Yamaoka T
    Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
    Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
    Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
    Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
    Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
    Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
    J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.
    Hanada M; Mizuno S; Fukushima A; Saito Y; Noguchi T; Yamaoka T
    Jpn J Cancer Res; 1998 Nov; 89(11):1229-38. PubMed ID: 9914793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amrubicin induces apoptosis in human tumor cells mediated by the activation of caspase-3/7 preceding a loss of mitochondrial membrane potential.
    Hanada M; Noguchi T; Yamaoka T
    Cancer Sci; 2006 Dec; 97(12):1396-403. PubMed ID: 16995876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
    Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
    Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
    Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].
    Ohsawa M; Demizu M; Chihara S; Ueda H; Igarashi T; Tomiyama N; Nakashima Y; Hosoi K; Min K
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1311-4. PubMed ID: 19692770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
    Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
    J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents].
    Hamada A
    Yakugaku Zasshi; 2005 Aug; 125(8):631-7. PubMed ID: 16079613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.